New whooping cough vaccine passes major safety check in 2,400 adults
NCT ID NCT06798831
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests the safety of a new whooping cough (pertussis) vaccine in about 2,400 healthy adults aged 18 to 75. Participants receive a single booster dose, and researchers watch for side effects over 28 days. The goal is to confirm the vaccine is safe and to check that different batches produce consistent results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS VACCINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chula Clinical Research Center (Chula CRC)
Bangkok, Bangkok, 10330, Thailand
-
Queen Saovabha Memorial Institute, Thai Red Cross Society
Bangkok, Bangkok, 10330, Thailand
-
Thai Red Cross AIDS and Infectious Diseases Research Centre
Bangkok, Bangkok, 10330, Thailand
Conditions
Explore the condition pages connected to this study.